Gary Raskob to Partial Thromboplastin Time
This is a "connection" page, showing publications Gary Raskob has written about Partial Thromboplastin Time.
Connection Strength
0.213
-
Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021 08 12; 385(7):609-617.
Score: 0.048
-
Different effects of heparin in males and females. Clin Invest Med. 1998 Apr; 21(2):71-8.
Score: 0.038
-
Monitoring low-dose warfarin therapy by a central laboratory and implications for clinical trials and patient care. The Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1996 Nov 01; 78(9):1074-6.
Score: 0.035
-
Aging and heparin-related bleeding. Arch Intern Med. 1996 Apr 22; 156(8):857-60.
Score: 0.033
-
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015 Jan 15; 372(3):232-40.
Score: 0.030
-
Physician-guided treatment compared with a heparin protocol for deep vein thrombosis. Arch Intern Med. 1994 May 09; 154(9):999-1004.
Score: 0.007
-
Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med. 1992 Aug; 152(8):1589-95.
Score: 0.006
-
Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992 Apr 09; 326(15):975-82.
Score: 0.006
-
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986 Oct 30; 315(18):1109-14.
Score: 0.004
-
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982 Dec 30; 307(27):1676-81.
Score: 0.003